Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer

BACKGROUND: Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic colorectal cancer (mCRC). The aim of this study was to evaluate the efficacy and safety of this regimen in combination with bevacizumab (BV), as first-line treatment for m...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: García-Alfonso, P, Muñoz-Martin, A J, Alvarez-Suarez, S, Jerez-Gilarranz, Y, Riesco-Martinez, M, Khosravi, P, Martin, M
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group 2010
Onderwerpen:
Clinical Study
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2990572/
https://ncbi.nlm.nih.gov/pubmed/20978503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605907
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items